The Ruminant Wellbeing Achievement Award will be offered to a practising veterinary surgeon or a researcher in veterinary science, animal science or related disciplines to recognise his/her achievements in advancing the well-being of ruminants.
The Ruminant Wellbeing Research Award will be offered to a recent PhD graduate in veterinary science, animal science or related disciplines that made an exceptional contribution to the scientific knowledge on ruminant well-being.
The winners will be awarded with a €10,000 cash prize. Travel expenses to attend the meeting and awards ceremony (which coincides with the World Buiatrics meeting) will also be covered.
Scott Deakin, Metacam brand manager at Boehringer said: "Farm animal wellbeing is at the heart of efficient and effective production and Boehringer is delighted to have led the way in raising the importance of this over the last 10 years and is committed to doing so for the next 10 years and beyond.
"By linking with the World Buiatrics Association for the first time and offering two awards at the Wellbeing Forum, we believe the company is offering an exciting and valuable opportunity for vets and we look forward to receiving a large number of interesting applications."
Veterinary surgeons can apply directly or nominate a colleague at: www.farmanimalwellbeing.com.
An independent jury will decide on the winner.
The deadline for applications is 28th February 2018.
Reverse wound bandages are made with the adhesive on the outside and design printed on the inside, making it easier to apply the bandage without over-tightening.
The company says it has launched the new reverse-wound bandage in response to demand from veterinary practices.
The bandages come in two widths: five and 7.5 cm, in a range of colours and designs which were chosen by veterinary nurses. They are 2.2m long, stretching to 4.5m, and J.A.K Marketing says they are super flexible, lightweight and easy to tear.
For more information, visit: https://www.jakmarketing.co.uk/products/aniwrap-sketch.html
Musculoskeletal therapists currently have their work underpinned by an Exemption Order to the Veterinary Surgeons Act 1966 which allows them to treat an animal under the direction of a veterinary surgeon who has first examined that animal.
The College says it has recognised that there has been confusion over whether musculoskeletal therapists need a veterinary referral for maintenance work, such as massage, in a healthy animal. This may lead to delays in animals receiving maintenance care.
The new guidance, found in Chapter 19 (www.rcvs.org.uk/unqualified) of the supporting guidance to the Code of Professional Conduct, sets out the existing rules for musculoskeletal treatment of illness, disease or pathology, and clarifies that healthy animals do not need a veterinary referral for maintenance care.
The guidance stresses that musculoskeletal therapists are part of the vet-led team, and that any animal, including healthy ones, should be registered with a veterinary surgeon and referred to a vet at the first sign of any symptoms that may suggest underlying health issues.
The guidance also says that vets should be confident that the musculoskeletal therapist is appropriately qualified; indicators of this can include membership of a voluntary regulatory body with a register of practitioners, and associated standards of education and conduct, supported by a complaints and disciplinary process.
In March 2019 the RCVS published the Review of Minor Procedures Regime (www.rcvs.org.uk/document-library/report-to-defra-on-the-review-of-minor-procedures-regime-and/) which noted that the existing exemption order was not suitable for underpinning the work of musculoskeletal therapists, and recommended that this be remedied by reform of Schedule 3 of the Veterinary Surgeons Act, alongside regulation by the RCVS through Associate status for musculoskeletal therapists.
This would allow the RCVS to set and uphold standards for musculoskeletal therapists in a similar way to veterinary nurses, giving further assurance to both the veterinary professions and the public. The recent Legislation Working Party Report recommendations builds on that recommendation, and is currently open for consultation at www.rcvs.org.uk/consultations
MWI Veterinary Supply Inc, the parent company of Centaur Services, has acquired practice management software company Vetspace in order to offer practices wholesaler services that are better integrated with their practice management system.
Vetspace, formerly Jupiter Systems, has been developing and providing server and cloud-based practice management software for veterinary practices since 1989. There are over 1,000 installations of Vetspace's software solutions in the UK.
The recent acquisition by MWI Veterinary Supply sees Vetspace joining a group of companies including Centaur Services and Securos, a manufacturer and supplier of veterinary orthopedic solutions.
Centaur Services' core business is the daily delivery of products required by UK veterinary practices. MWI says Vetspace customers will now benefit from an enhanced level of customer service, innovative product development, technological investment and an opportunity for greater integration between their practice management software and wholesaler - all backed by the experience and investment of a global parent company.
Centaur Services customers may continue to use any other practice management system, whilst Vetspace customers may continue to work with other wholesalers. Brian Topper, Managing Director of Centaur Services said: "We're very pleased to be able to offer our customers throughout the UK the opportunity to further enhance and streamline their practices by integrating their practice management system and wholesaler solution. Our focus is on delivering a high quality service that's accurate and reliable and we believe that aligning our offer with that of Vetspace will have major benefits for the future of both ours and our customers' businesses."
Nader Pour of Vetspace added: "Having been at the forefront of practice management software for the past 25 years we are delighted to be joining the MWI Veterinary Supply group and working with the likes of Centaur Services to further develop the benefits we're able to offer our customers for the next 25 years and beyond."
Picture shows, left to right: Brian Topper, Centaur Services, Nader Pour, Vetspace and Jim Cleary, CEO of MWI.
The survey is very quick: sub two minutes. It asks simply whether you agree or not, and what you think are the benefits and drawbacks of remote consulting without otherwise knowing or seeing the animal.
All individual replies are strictly confidential and will not be shared with anyone. Your name is only asked for validation purposes.
To take part: https://survey.alchemer.com/s3/7235757/Remote-Consultation-Survey
The results will be published within a week.
Vétoquinol has released the results of a survey of 1000 dog owners, which looked into their attitudes towards long-term medication for their pet1.
Owners were asked to rate how important various factors were to them when it came to giving medicine long term to their dog. They were also asked to consider what they felt was most important to their vet when it came to choosing a medicine.
Vétoquinol says the fact that dog owners rate the effectiveness of a medication much more highly than the cost means there is very little reason to compromise on treatment based on a presumption of what clients will want to pay. These findings are also largely very positive in that they suggest that dog owners believe that in many areas vets are making decisions based on criteria that are important to owners. The area where there is the greatest mismatch is over the risk of side effects of medication.
Pet owners think that vets may take the risk of side effects from long-term medications less seriously than the owners themselves might prefer. It suggests that the risk of potential harm, no matter how small the risk of actual harm is, may be more unacceptable to the dog owner than vets and nurses might otherwise presume. When prescribing long-term medication there is a need to talk about the risks associated with medication more openly and to take the client's attitudes to risk into consideration.
1. A survey of 1048 dog owners, carried out by petbuzz, on behalf of Vétoquinol, March 2011
Alstoe Animal Health has announced that Vetergesic (buprenorphine), the UK's most commonly used injectable opiate for small animal use, is now registered for use in horses.
Developed and manufactured in the UK, Alstoe took over marketing Vetergesic 11 years ago. Two years ago the company introduced the Multi-Dose Pack, which it says allows veterinary surgeons to manage the larger liquid volumes required in horses more easily.
Alstoe says Vetergesic potentiates sedative drugs for standing sedation or routine premedication and provides profound centrally acting analgesic effects for up to nine hours. In routine procedures, this allows good recoveries and a rapid return to normal behaviour patterns.
Alstoe also says that in a thermal anti-nociceptive study carried out at Bristol University, Vetergesic showed significantly better analgesic effects than butorphanol. Field studies carried out in the UK also confirmed that when combined with a sedative, Vetergesic can provide up to 60 minutes of operating time, with smooth and quick recoveries.
John Nellis of Alstoe said: "We have invested heavily in this product and are confident that the rewards enjoyed by small animal vets will also be appreciated by their equine colleagues. We call Vetergesic 'the thoroughbred of pain management'."
Vetergesic Multidose is available for dogs, cats and horses in a 10 ml vial.
Alstoe offers an hour long explanatory seminar, which can be delivered directly to practice members. An 8 page brochure and 'pocket-sized' dose chart are also available. Further details from Alstoe on: 01347 878606 or email: info@alstoe.co.uk .
In current regional anaesthesia procedures two operators are often needed, with an assistant using 'feel' to inject the anaesthetic solution at the required pressure. This, says the company, means anaesthetic solutions can be injected at unsafe pressures. The new device incorporates a safety system that limits injection pressure, to reduce the risk of nerve injury.
Dr. Federico Corletto, Consultant Anaesthetist from Dick White Referrals said: “By turning regional anaesthesia into a one-person procedure, the technology also removes the challenges of communicating with an assistant regarding subjective injective pressure feel, thus removing the unpredictability of an untrained hand.”
Medovate says the use of ultrasound guided regional anaesthesia is becoming more common practice today, with the technique – which can help provide a higher level of visualisation for the practitioner – increasingly seen as a ‘gold standard’.
However, there are limitations and challenges that are not always present in the practice of adult human medicine. Nerve parathesia, for instance, is harder to ascertain in animals. Small animals such as cats also have increased sensitivity to local anaesthetics when compared with other species, necessitating much lower maximum doses be used.1
Brett Hughes, Homecare & Veterinary Business Manager at Vygon UK, said: "The device infuses at 0.5ml/second, and to vets the technology offers a valuable tool that can control injection small intervals at a time. This allows the veterinary practitioner to titrate appropriately to see the anaesthesia spread around a nerve bundle.
"There are a significant number of regional anaesthesia blocks completed in veterinary practice per annum globally, so potentially this NHS developed device could play a major role in the future of veterinary practice."
For more information, visit: https://www.medovate.co.uk/veterinary/safira-for-veterinary-applications and https://www.vygonvet.co.uk/
Reference
The Lintbells Mobility Matters initiative provides materials designed to help improve communication and client understanding of their pet’s condition. It includes a guide on how to set up a mobility-focused nurse-led clinic, together with a step-by-step guide in a flip chart format to help RVNs recommend dietary supplements or modifications.
To help launch the clinic, Lintbells Veterinary Business Development Executives can provide lunch and learn sessions. Practices can also become approved Mobility Matters practices with certified CPD for the whole team to ensure that the process of recommendation and referral to the clinic occurs seamlessly and involves everyone in the practice.
Yumove Brand Manager Gemma Cunningham said: "Feedback about the pack is that it helps vets and vet nurses explain mobility problems to owners in a simple but structured way to improve buy-in to a multimodal approach".
Practices that want to register an interest in the initiative can contact their local Lintbells Veterinary Business Development Executive or visit www.lintbellsvet.com.
In the survey of 354 owners, 65% thought their cats get on well with each other. However, 60% reported signs of disharmony, including: chasing (65%), swiping paws (53%), hissing (48%), keeping a distance from one another (31%), fighting and acting aggressively (27%), staring (30%) and sitting in front of resources to block access (25%).
In addition, some of the cats were so stressed that they would often scratch furniture or household items (46%), hide from their housemates (26%), meow excessively (20%) or spray (17%).
Claire Russell, Feliway brand manager at Ceva Animal Health, said: "There is the common misconception that cats need other feline companions, however they are naturally solitary survivors who are more than happy in their own company. Simple environmental changes and using Feliway Friends can help restore harmony between household cats who are displaying signs of multi-cat tension."
This study was conducted in collaboration with the Waltham Centre for Pet Nutrition as part of a larger study, led by Prof Claire Hughes at the University of Cambridge Centre for Family Research.
Researchers surveyed 12-year-old children from 77 families with one or more pets of any type and more than one child at home. Children reported strong relationships with their pets relative to their siblings, with lower levels of conflict and greater satisfaction in owners of dogs than other kinds of pets.
The authors say this research adds to increasing evidence that household pets may have a major influence on child development, and could have a positive impact on children’s social skills and emotional well-being.
Pets are almost as common as siblings in western households, although there are relatively few studies on the importance of child-pet relationships.
Matt Cassells, lead researcher, said: "Anyone who has loved a childhood pet knows that we turn to them for companionship and disclosure, just like relationships between people. We wanted to know how strong these relationships are with pets relative to other close family ties. Ultimately this may enable us to understand how animals contribute to healthy child development."
He added: "Even though pets may not fully understand or respond verbally, the level of disclosure to pets was no less than to siblings.
"The fact that pets cannot understand or talk back may even be a benefit as it means they are completely non-judgmental. While previous research has often found that boys report stronger relationships with their pets than girls do, we actually found the opposite. While boys and girls were equally satisfied with their pets, girls reported more disclosure, companionship, and conflict with their pet than did boys, perhaps indicating that girls may interact with their pets in more nuanced ways."
Waltham researcher Nancy Gee, a co-author of the study, said: "Evidence continues to grow showing that pets have positive benefits on human health and community cohesion. The social support that adolescents receive from pets may well support psychological well-being later in life but there is still more to learn about the long term impact of pets on children’s development."
A group of some of the best-known referral practices in the country has issued a formal response to the recent announcement by pet insurance underwriter RSA that it is building a network of preferred referral practices to direct its clients to.
Whilst RSA has clarified the contents of a letter it sent to practices in the Midlands and North West, and apologised to the profession for the confusion it caused, it has not yet responded to any of the other concerns raised by the profession.
Perhaps chief amongst those is the claim by RSA's Head of Pet Claims, Keith Maxwell, that the company is looking to provide like-for-like treatment at a lower cost from its list of preferred referral practices.
Referral vets from Anderson Moores Veterinary Specialists in Hampshire, Cave Veterinary Specialists in Somerset, Davies Veterinary Specialists in Hertfordshire, Dick White Referrals in Suffolk, North Downs Specialist Referrals in Surrey, The Veterinary Cardiorespiratory Centre in Warwickshire and Willows Veterinary Centre in the West Midlands say that RSA's current list is simply not representative of the RCVS Recognised Specialist expertise and advanced therapies available within the veterinary profession, thereby making it impossible for RSA to offer like-for-like treatment, let alone at a lower cost.
Clive Elwood, Managing Director of Davies Veterinary Specialists in Hertfordshire, speaking on behalf of the practices who have expressed concern about the move, said: "An approach that focuses on cost-cutting rather than quality of patient care and lacks any genuine or objective process to benchmark clinical standards is inappropriate. Many multi-disciplinary centres place enormous value on the importance of Recognised Specialists being involved at every level of care including consultation, anaesthesia and imaging assessment and the proposed restrictions may preclude this level of service in some instances. We understand that balancing high standards of care and affordability for owners and insurance companies is an important issue and we hope insurers will work with all sectors of the profession to find constructive workable long term solutions."
Mike Martin of the Veterinary Cardiorespiratory Centre in Warwickshire added: "Owners buy pet insurance to ensure that they can access the best available expertise when their animals are ill. I don't think any owner wants to have their choice of practice restricted by insurance companies who are primarily concerned with encouraging shortcuts to reduce costs."
The British College of Veterinary Specialists has invited RSA to attend a meeting to discuss issues of concern, but says it hasn't thus far received a reply.
Dechra says phenobarbital is effective as a monotherapy in 60 to 80 per cent of dogs with idiopathic epilepsy, but that in 40% of dogs, seizures cannot be controlled with phenobarbital alone. In these cases the company's potassium bromide treatment Libromide, is licensed to be used alongside Soliphen as a concurrent therapy.
According to the company, the combination of phenobarbital and potassium bromide has been shown to reduce seizure number and severity in dogs with refractory idiopathic epilepsy; in tests, the combination treatment reduced the mean seizure rate from 27.4 seizures per month to 2.2 seizures.
Dechra Veterinary Products Brand Manager Craig Sankey said: "Epilepsy is the most common chronic canine neurological disorder, affecting around 0.62 per cent of dogs.
"It can be a distressing condition for both the animal and its owner so we are launching a therapy that can reduce the number of seizures in even the most challenging cases.
"We have also produced new guidelines for prescribing vets, detailing step by step how the treatments can act alone or concurrently. We believe using Soliphen as a sole therapy or in conjunction with Libromide will make a positive contribution to veterinary professionals in their ongoing treatment and management of dogs with epilepsy."
For more information, visit www.dechra.co.uk
In 2009, Chiara (pictured right) was the first to be awarded by examination the title of European Veterinary Specialist in Oncology after completing a one-year small animal internship at the University of Glasgow and a three-year residency in internal medicine and oncology at the University of Edinburgh.
Alongside her clinical work, Chiara is an honorary lecturer at the University of Liverpool and a multi-lingual specialist consultant, writer and lecturer at events in the UK and Europe. Her focus is on postgraduate training in small animal oncology and internal medicine and online education of pet owners and animal carers. Chiara is a member of the general and oncology examination committees of the European College of Veterinary Internal Medicine (ECVIM).
She said: "My aim is to provide veterinarians and owners on a daily basis with the most up-to-date information on cancer diagnosis and treatment options so pets can spend more time with their families whilst protecting their quality of life and preventing suffering."
Samuela is a European Specialist in Veterinary Ophthalmology with a special interest in ocular pathology as well as corneal disease and surgery.
She said: "Working at Willows allows me to be part of a talented and passionate team, and a chance to become the best ophthalmologist I can. Willows offers a very high level of patient care, and working here gives me the opportunity for constant scientific and clinical development."
The survey polled 671 veterinary surgeons in May and June 2017.
92% of those who are now in non-clinical roles had worked in clinical practice in the past. 73% had previously worked in mixed practice, 49% in companion animal practice, 33% in production animal practice and 8% in equine practice.
32% are now in academia, whilst 21% have moved to work in commerce and industry.
Mostly, veterinary surgeons gave positive reasons for moving to non-clinical work: 43% said they were looking for a new challenge and 33% said they were looking for a different type of work.
Others were looking to improve their work-life balance: 24% said they wanted a role with no out-of-hours work, 14% said they wanted more flexible working hours and 10% said clinical work was incompatible with family or outside commitments.
21% cited difficulty in progressing with their clinical career as a reason for moving whilst 19% said they were looking for less stress at work.
There were some differences between men and women in the timing of their career change and the reasons behind it. Women tended to leave clinical practice earlier in their career; an average of 6.5 years after they qualified compared to 8 years for men.
Reasons related to working hours and flexibility were more prominent motivations for women to move from clinical practice (54% of female vets compared to 31% of male vets). On the other hand, male vets were more likely than female vets to cite reasons related to a desire to do a different type of work (44% of male vets compared to 24% of female vets).
BVA Senior Vice President, Gudrun Ravetz said: "These figures show that there is a sizeable percentage of practising vets who are making the move into non-clinical roles and that there are a variety of reasons behind their decision. There is a huge diversity of career paths open to vets and it’s important both for those who are already in practice and for those considering a veterinary career to be aware of all the options available.
"I have had a portfolio career myself that involved clinical practice in all different business models including charity practice and industry and I know that the most important thing is for vets to feel fulfilled in their chosen roles and understand that there is a wide range of opportunity available to them.
"However, we also know that practices are seriously worried about being able to recruit and retain staff. Looking at the reasons for leaving – including a desire for more flexibility, a better work/life balance, and concerns about stress – this has to be a wake-up call to all employers to think about whether we can do things differently to support our colleagues.
"BVA has a role to play too and many of the Vet Futures actions are designed to address these issues, including the workforce study commissioned by BVA, the development of a careers hub, and our support for the Mind Matters Initiative led by RCVS, amongst others. These are issues that the profession must tackle together."
The study "Influence of dietary restriction and low-intensity exercise on weight loss and insulin sensitivity in obese equids" was carried out by Nick Bamford and colleagues at the University of Melbourne’s Faculty of Veterinary and Agricultural Science, in collaboration with Spillers.
A total of 24 obese horses and ponies were randomly divided into two groups; 'restricted diet only' or 'restricted diet plus exercise'. All horses and ponies were fed the same diet of restricted hay (no grazing), a small amount of alfalfa chaff and soya bean meal, and a vitamin and mineral supplement.
The exercise programme, which was designed following feedback from horse owners to help ensure it could be implemented relatively easily in the real world, consisted of 15 minutes of brisk trotting (with a five minute walk before and after) five days per week for 12 weeks.
The 'restricted diet only' group showed an overall reduction in body weight and body condition score. They had increased levels of adiponectin – a hormone produced by fat cells, low levels of which are a risk factor for laminitis. They had decreased baseline insulin, high levels of which have been linked to an increased risk of laminitis, and decreased leptin, high levels of which are associated with obesity.
Although exercise did not increase weight loss, it did produce additional benefits that were not seen in the 'restricted diet only' group, the most important one being improved insulin sensitivity. More insulin sensitive horses and ponies need to produce less insulin in order to control their blood sugar. This is important because high levels of insulin in the blood and/or reduced insulin sensitivity are risk factors for laminitis. Horses and ponies in the exercise group also had decreased levels of ‘serum amyloid A’, a protein that is a marker for inflammation.
Clare Barfoot RNutr, the research and development manager at Spillers said: "Reducing calorie intake and feeding a diet low in starch and sugar should be the priority for overweight horses and ponies. However, the results of this study suggest that exercise may offer additional health benefits for obese horses and ponies and/or those with ‘EMS’ that cannot be achieved by cutting calories and weight loss alone."
Photo: Spillers/Steve Bardens
Dechra Veterinary Products has relaunched Oxyglobin after concluding an exclusive agreement to supply the product across the UK and Republic of Ireland.
Oxyglobin is used to stabilise anaemic dogs until the underlying condition can be controlled and the animal's body can produce its own new red blood cells.
Dechra says the treatment, which is now available in both 125ml bags and individual 60ml transfusion bags, maintains tissue oxygenation even when there is severe stenosis of blood vessels. It has a viscosity which is more than water but less than blood for ease of flow through vessels, and also increases circulatory volume.
Dechra Veterinary Products Brand Manager, Carol Morgan, said: "Veterinary professionals have been waiting for Oxyglobin to come back onto the market for some time and we're delighted to be able to relaunch it in the UK and Republic of Ireland.
"It was withdrawn from the market in 2010 when OPK Biotech acquired the assets of manufacturer Biopure Corporation in 2009. But this year, OPK Biotech resumed the manufacture of Oxyglobin and we have stocks available to practices from this month (FEB)."
"Oxyglobin turns around clinical outcomes for dogs with anaemia, regardless of the cause of the condition, which is why it is the objective choice for safety, effectiveness and convenience.
"Oxyglobin is the only oxygen-carrying fluid available off the shelf for dogs in need of oxygen support and no typing or cross-matching of the recipient's blood is required."
Oxyglobin, a sterile formulation of polymerised purified bovine haemoglobin in a balanced salt solution with proven efficacy, is available in single dose 60ml and 125ml infusion bags.
For further information on Oxyglobin, see www.dechra.co.uk
To mark today's European Antibiotic Awareness Day 2010, the British Veterinary Association is warning veterinary surgeons in the UK that failure to use antimicrobials responsibly could result in their use being restricted.
The BVA promotes the responsible use of antimicrobials and last year published a poster and guidance for vets: 'Responsible use of antimicrobials in veterinary practice: the 8-point plan'. According to the association, the poster received very positive feedback from across the UK and from the Federation of Veterinarians of Europe (FVE).
Concerns regarding resistance to antimicrobials and antibiotics span both the human and animal medicine fields and in 2008 the Chief Medical Officer called for a ban on the use of certain types of antibiotics in animals in order to protect their activity in humans.
Furthermore some EU Member States already restrict the availability of antimicrobials to veterinary surgeons and adopt a strict formulary approach to the medicines that they can prescribe. The BVA says it is concerned that this trend will reach the UK and the freedom of vets to prescribe according to their clinical judgement will be restricted.
Harvey Locke, President of the BVA, said: "Antimicrobial resistance is an enormous problem for both human and animal health. As veterinary surgeons we have a duty to use these medicines responsibly for the good of animal health and welfare as well as public health.
"The BVA's poster on responsible use should be displayed in veterinary practices across the UK as a constant reminder, and I would urge all vets to refer to it.
"Failure to heed the message of responsible use could result in vets losing the right to prescribe certain medicines, which could have a significant impact on animal health and welfare.
"On Antibiotic Awareness Day our message to vets is clear: use them responsibly or lose them."
Is it right to keep treating an animal just because the technology is available? This is a question that Noel Fitzpatrick, aka the BBC's Bionic Vet, will be addressing at this year's British Veterinary Association (BVA) Congress, in a debate titled 'Treatment too far?' on Friday 24th September at 4pm.
The BVA Congress will take place in the Glasgow Marriott Hotel on 23-25 September 2010 under the theme 'Vets and the Public Good', looking at the role of veterinary surgeons in all aspects of society.
Organisers say that Congress will be a truly Scottish event, led by BVA President Professor Bill Reilly (born and bred in Glasgow and a graduate of Glasgow Vet School) with clinical CPD sessions delivered by Scotland's finest research and academic institutions.
This year also boasts a full non-clinical stream of lectures tackling employment law, management skills, and mental health.
Highlights include:
Vets and the public good: the broader perspective (Wooldridge Memorial Lecture)Professor Stuart Reid, Dean of the Faculty of Veterinary Medicine at the University of Glasgow will deliver the keynote Wooldridge Memorial Lecture. He will consider the extent of the veterinary contribution to society, which extends into areas such as public health, infectious disease control, scientific research, public education, food production, national security, disaster management, care of the environment, and international development. (Fri 24 Sept, 12.15-13.25)
Pets and society: turning a blind eye to abuse?It is nearly a decade since attention began to be drawn to evidence of links between animal abuse and domestic violence towards humans. This session will examine the dilemmas confronting practising vets, asking at what stage should suspicions of abuse be reported and to whom? (Fri 24 Sept, 11.00-12.00)
Four into one must go Following last year's highly popular session, the UK's four CVOs will again come together to debate and discuss current issues in veterinary politics and animal health and welfare, under the chairmanship of BVA President Professor Bill Reilly. (Sat 25 Sept, 9.30-10.30)
Responsibility and cost sharing - where are we now? This session will include a progress report from Rosemary Radcliffe, chair of the independent committee that will be advising the Government on establishing new arrangements in England, and a discussion of what this might mean for practising vets. (Sat 25 Sept, 16.00-17.00)
In addition there will be contentious issue debates on the role of vets in promoting farm animal welfare, the practical difficulties of current dangerous dogs legislation, and the role of vets as experts witnesses in cases of abuse or neglect.
Under the theme of 'public good' there will be a session looking at the role of vets in international development 'Improving the livelihoods of farmers in resource-poor countries', and a session on the zoonotic infections that impact on public health, such as E. Coli and Chlamydia, and what organisations like open farms can do to minimise the risks.
Professor Bill Reilly, President of the BVA, said: "Vets and the public good has been the theme of my presidential term because I believe that the role of vets in all aspects of society should receive more attention.
"Our Congress programme combines the world-renowned expertise of Scotland's academic and research institutes with significant topical issues of debate to capture the widest possible definition of the veterinary contribution to society."
For more information on BVA Congress 2010 (including the full agenda and online registration) visit the BVA website www.bva.co.uk/congress
Novartis Animal Health has launched Onsior®, a coxib NSAID (non-steroidal anti-inflammatory drug) for the relief of pain and inflammation in both cats and dogs.
According to the company, NSAIDs traditionally inhibit both COX-2 and COX-1 enzymes which can result in common side effects involving the gastrointestinal tract and the kidneys. Onsior, however, targets the pain-causing COX-2 enzymes while sparing the protective actions of COX-1 and is the only coxib licensed for cats as well as dogs.
Novartis says tissue selectivity is a further benefit of Onsior. The drug travels rapidly through the bloodstream to the site of injury or irritation. It then concentrates at the point of inflammation, while exiting the bloodstream very quickly.
Dosed once daily, Novartis says Onsior has an excellent safety profile and fits different administration routes with pain and inflammatory indications, which are:
Kelly Doucette, DVM, Global Technical Services Manager with Novartis Animal Health said: "With the benefits of being tissue selective, sparing COX-1, and having a short blood half-life - as well as being approved for both cats and dogs - Onsior will stand out as the new pain reliever of choice for vets."
Folkert Kamphuis, COO Novartis Animal Health added: "Onsior covers multiple indications, works for cats and dogs, comes in two formulations - oral and injectable - and is very simple to dose, which allows veterinarians to use it as the cornerstone of pain management in their clinics. With this complete range, Onsior will offer veterinarians a convenient solution addressing all their different needs."
Eurovet Animal Health has launched Cardisure, a new look pimobendan which the company claims will help deliver more precise dosing in the treatment of cardiac disease.
Dogs have the widest range in bodyweight of any species, and it's long been a problem accommodating the wide variation in dosage requirements that this leads to. Having to give too many tablets in a day or the need to split small tablets can be very discouraging to owners and may lead to poorer rates of compliance.
Cardisure is available in 1.25 mg, 2.5 mg, 5 mg tablets and a 10 mg tablet size. Eurovet says the tablets are easily divisible and palatable, making it easier all round for pet owners to administer the right dose of medication to their pet.
Eurovet says the benefits of treating heart disease with pimobendan are well-established and that Cardisure gives clinicians a few more client-friendly options when it comes to treating heart disease, as well as being available in smart and professional blister packs for easy dispensing.
The pads contain ophytrium and chlorhexidine at 3%. Ophytrium is a purified natural ingredient from Ophiopogon japonicus which, Ceva says, strengthens the mechanical skin barrier1, restores the balance of protective microbial flora2 and reduces irritation, while soothing the skin1. Chlorhexidine is both antibacterial and antifungal.
Ceva says that Douxo S3 Pyo pads, which come in packs of 30, provide antibacterial and antifungal efficacy within one minute and are free from soap, parabens, sulphates, phthalates, colourants and nanoparticles.
They are available in a new, hypoallergenic ‘summertime’ fragrance which pet owners liken to coconut and vanilla.
The pads add to the Douxo S3 Pyo range, which also consists of shampoo and a mousse.
Andrew Fullerton BVSc (Hons) MRCVS, product manager for Douxo S3 at Ceva said: "The new Douxo S3 range has been well received by both veterinary professionals and their clients since its launch, who find that the products are not only effective and well tolerated, but also easy-to-use. The Douxo S3 Pyo pads will enhance this range by offering an easy-to-administer antiseptic action while hydrating and maintaining the skin’s ecosystem.”
For further information, contact cevauk@ceva.com, your local territory manager or visit https://www.douxo.com/uk/Pet-Skin-Care/douxo-s3.
References
Whilst the decision has been welcomed by the BVA and leading animal charities, it has not been entirely free of controversy. According to various reports, the Press Association has seen a letter from Defra to the Royal Veterinary College in February this year, which said the scientific studies it had commissioned were 'not strong enough to support a ban'.
Talking to the BBC, Ian Gregory, a lobbyist for pet collar manufacturers said that charities had also exaggerated the shock delivered by the collars, which at typically one millijoule is 1000 times less than cattle fencing. He argued that: "The anecdotal problems reported with pet collars can be resolved by product standards rather than by banning a proven technology".
The government has stopped short of banning invisible fencing systems which can keep pets away from roads, saying that the devices are particularly useful for cat owners and animals often respond well to invisible fencing and quickly learn to stay within a boundary without receiving a static pulse.
BVA President John Fishwick said: "As we review the latest evidence on the welfare impact of pulse pet containment fences, we would like to see them covered by a code of practice, as well as the regulation of the sale of these devices and manufacturer’s instructions, to ensure that the potential adverse effects of use are highlighted to animal owners and consumers."
Photo: Shutterstock
Novartis Animal Health has announced the launch of Strenzen, an oral water medication for pigs, indicated for the treatment of gastrointestinal infections caused by Escherichia coli, Clostridium perfringens and Salmonella Typhimurium, and for respiratory tract infections caused by Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Strenzen contains contains a combination of amoxicillin trihydrate (500 mg/g) and potassium clavulanate (125 mg/g) in ratio of 4:1. Novartis says it is ideally suited for the treatment of post-weaning infections in pigs.
According to the company, the combination of amoxicillin and clavulanic acid broadens the performance of amoxicillin1,2, especially against resistant strains of bacteria capable of producing ß-lactamase enzymes. Certain bacteria are able to produce ß-lactamase enzymes as a protection mechanism, making the amoxicillin molecule ineffective against them. The clavulanic acid in Strenzen binds to the molecules of the ß-lactamase enzyme, ensuring the amoxicillin remains unaffected and free to attack bacteria. Prof. Dominiek Maes, DVM, MSc, MS, PhD, Dipl. ECVPH, Dipl. ECPHM, from the Porcine Health Management Unit of the Ghent University, Belgium said: "Weaning is a stressful event for piglets and there are several opportunistic diseases that can impact them during this period. The challenge with E. coli and S. suis infections is that in many countries there are currently no commercial vaccines available with proper efficacy. I believe Strenzen can indeed be very helpful in managing those infections which are so prevalent after weaning."
Novartis says Strenzen is rapidly excreted, leading to a withdrawal period of one day, which in turn maximizes production flexibility for pig producers. In addition, the water-soluble formulation of Strenzen ensures that treated pigs get a therapeutic dose even when they stop eating, making it an ideal treatment for sick pigs with compromised appetites.
Recent field trials on infected farms in Spain and the Czech Republic demonstrated that Strenzen-treated pigs give better production performance, better economic returns and require less medical intervention3,4,5. The reduction of the overall amount of antibiotics needed to treat severe post-weaning infections not only saves producers the costs of the labour and the medication, but is also important in regard to the development of resistance in bacteria.
Dr. Ulrich Klein, Global Technical Services Manager, Novartis Animal Health said: "With the launch of Strenzen, Novartis Animal Health demonstrates its commitment to continually broadening our product portfolio to address the specific needs of farmers and food producers. Strenzen has the ideal spectrum for the treatment of post-weaning infections, delivering better productivity results than current therapies for those infections."
The webinar, which is presented by equine internal medicine specialist David Rendle from Rainbow Equine Hospital, challenges some of the current perceptions of worm control in horses and explains why veterinary surgeons need to engage more with horse owners on the topic to ensure a sustainable approach to parasite control.
Supported by Virbac, maker of Equimax and Eraquell horse wormers, the webinar is free to BEVA members at http://www.ebeva.org/webinar74.